Source comparison
Tesamorelin Pharmacokinetics: Research Compound Comparison
Tesamorelin 26–38 minutes 0.15 hours (9 min) ~4% DPP-4 and NEP enzymatic degradation in plasma Mimics physiological GHRH pulsatility. Ideal for daily pulsatile GH release without receptor desensitization Sermorelin 10–20 minutes 0.08 hours (5 min) ~2% Rapid DP
This comparison does not assign a generated winner or score.
- Tesamorelin
- 26–38 minutes
- 0.15 hours (9 min)
- ~4%
- DPP-4 and NEP enzymatic degradation in plasma
- Mimics physiological GHRH pulsatility. Ideal for daily pulsatile GH release without receptor desensitization
- Sermorelin
- 10–20 minutes
- 0.08 hours (5 min)
- ~2%
- Rapid DPP-4 cleavage (no protective modifications)
- Faster clearance than tesamorelin but lower stability. Less consistent IGF-1 response across protocols
- CJC-1295 (DAC)
- 6–8 days
- 1–2 hours
- ~75%
- Slow albumin-mediated release and renal filtration
- Long half-life causes sustained GH elevation. Higher risk of receptor downregulation with chronic use
- Native GHRH (1-44)
- 7 minutes
- 0.05 hours (3 min)
- <1%
- Immediate DPP-4 degradation (no modifications)
- Extremely short-lived. Impractical for research dosing outside controlled IV infusion studies
- Modified GHRPs (e.g., Ipamorelin)
- 2 hours
- 0.75 hours (45 min)
- ~40%
- Hepatic metabolism and renal clearance
- Longer-acting than GHRH analogs but ghrelin-mimetic mechanism introduces appetite modulation as confounding variable